ELV: Flat Base detected on 14 Apr 2026

ELV is forming a flat base pattern with the stock at $316.07, sitting between strong support at $273.18 and resistance at $322.12. The pattern structure scores 13.0/15, breakout momentum at 11.0/13, and volume at 12.0/12 for a solid 78 overall score. RSI at 59.68 indicates room for upside without overbought extremes. The pattern has already developed an ascending triangle (pattern quality 35.0, formed Feb 27) and inverse head-and-shoulders (quality 34.0, formed Feb 11), suggesting multiple bullish configurations are layering at current price. The stock is trading 7.1% above its 20-day SMA, confirming near-term demand momentum.

On April 7, 2026, CMS confirmed Medicare Advantage and Part D plans will receive a 2.48% average rate increase for 2027, providing a significant catalyst that has driven ELV's recent 4.45% weekly and 10.36% two-week gains. ELV will release Q1 2026 financial results on April 22, 2026 at 6:00 a.m. EDT, creating near-term event risk just eight days away. Recent share gains are attributed to consistent earnings beat patterns, with the company surpassing consensus by $0.23 per share in the last quarter ($3.33 vs $3.10 estimate). However, analysts warn the Medicare Advantage rally may be largely priced in; Evercore ISI reinstated at Inline with $345 target, while 2026 faces an earnings trough with adjusted EPS guidance of $25.50 vs $30.29 in 2025. CMS notified Elevance on February 27 of intent to impose intermediate sanctions suspending Medicare Advantage enrollment, effective May 30.

A successful breakout above $322.12 resistance targets the conservative measured move of $329.77, with a win probability of 66.84%. The pattern would require volume persistence above the current 1.06x ratio and closing above resistance on elevated turnover to confirm genuine breakout. Invalidation occurs at the key support level of $273.18, representing 13.7% downside risk from current price. Given the ascending triangle also detected here, a break above $322 could extend toward the 50-day moving average near $335–$340 zone where previous resistance clusters.

The Medicare rate catalyst may already be fully priced in per analyst reassessment; 2026 represents an earnings trough with EPS declining from $30.29 to $25.50. CMS sanctions threatening Medicare Advantage enrollment suspension through May 30 create binary event risk; Medicaid margins are projected at negative 1.75% for 2026 with high-teens percentage membership declines expected. Elevance faces structural headwinds: quarterly revenue missed estimates by 1.04% despite 10% YoY growth, and shrinking membership in key segments could weigh on future growth. Earnings report on April 22 (eight days forward) could disrupt the pattern if guidance misses or management sounds cautious on 2027 recovery. ATR volatility at 2.7% is moderate but beta of 1.02 offers no downside cushion in market downturns.